Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation.
Share Price & News
How has Catalyst Biosciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CBIO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: CBIO's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: CBIO underperformed the US Biotechs industry which returned 25.9% over the past year.
Return vs Market: CBIO underperformed the US Market which returned 33% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Catalyst Biosciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StDo Institutions Own Catalyst Biosciences, Inc. (NASDAQ:CBIO) Shares?
3 months ago | Simply Wall StShareholders May Not Be So Generous With Catalyst Biosciences, Inc.'s (NASDAQ:CBIO) CEO Compensation And Here's Why
4 months ago | Simply Wall StCatalyst Biosciences (NASDAQ:CBIO) Will Have To Spend Its Cash Wisely
Catalyst Biosciences Fundamentals Summary
|CBIO fundamental statistics|
Is CBIO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CBIO income statement (TTM)|
|Cost of Revenue||US$63.97m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.97|
|Net Profit Margin||-1,399.71%|
How did CBIO perform over the long term?See historical performance and comparison
Is Catalyst Biosciences undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CBIO ($4.9) is trading below our estimate of fair value ($72.8)
Significantly Below Fair Value: CBIO is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CBIO is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: CBIO is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CBIO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CBIO is good value based on its PB Ratio (1.8x) compared to the US Biotechs industry average (3.1x).
How is Catalyst Biosciences forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CBIO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CBIO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CBIO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CBIO's revenue (71.2% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: CBIO's revenue (71.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CBIO's Return on Equity is forecast to be high in 3 years time
How has Catalyst Biosciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CBIO is currently unprofitable.
Growing Profit Margin: CBIO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CBIO is unprofitable, and losses have increased over the past 5 years at a rate of 29.7% per year.
Accelerating Growth: Unable to compare CBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: CBIO has a negative Return on Equity (-90.77%), as it is currently unprofitable.
How is Catalyst Biosciences's financial position?
Financial Position Analysis
Short Term Liabilities: CBIO's short term assets ($96.8M) exceed its short term liabilities ($15.6M).
Long Term Liabilities: CBIO's short term assets ($96.8M) exceed its long term liabilities ($1.1M).
Debt to Equity History and Analysis
Debt Level: CBIO is debt free.
Reducing Debt: CBIO has no debt compared to 5 years ago when its debt to equity ratio was 129.4%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CBIO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CBIO has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 26.4% each year.
What is Catalyst Biosciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CBIO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CBIO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CBIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Nassim Usman (61 yo)
Dr. Nassim Usman, Ph.D. serves as a Venture Partner at Morgenthaler Ventures. Dr. Usman is a part of the life sciences team. He joined Morgenthaler as an Entrepreneur-in-Residence in 2005 and has also serv...
CEO Compensation Analysis
Compensation vs Market: Nassim's total compensation ($USD1.41M) is about average for companies of similar size in the US market ($USD1.10M).
Compensation vs Earnings: Nassim's compensation has increased whilst the company is unprofitable.
Experienced Management: CBIO's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Experienced Board: CBIO's board of directors are considered experienced (5.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CBIO insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 42.2%.
Catalyst Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Catalyst Biosciences, Inc.
- Ticker: CBIO
- Exchange: NasdaqCM
- Founded: 2002
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$162.474m
- Shares outstanding: 31.37m
- Website: https://www.catalystbiosciences.com
Number of Employees
- Catalyst Biosciences, Inc.
- 611 Gateway Boulevard
- Suite 710
- South San Francisco
- United States
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company engineer proteas...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/20 22:34|
|End of Day Share Price||2021/09/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.